This includes Abrysvo and Arexvy RSV vaccines.
On October 15, we reported in The Link that the respiratory syncytial virus (RSV) vaccine Abrysvo, which is offered through the provincially funded immunization program to eligible Albertans, is categorized as a Schedule II drug.
It should be noted that all RSV vaccines, including Arexvy, are categorized as Schedule II, regardless if they are offered through the provincially funded immunization program or not.
More information about the provincially funded immunization program can be found within the Alberta Immunization Policy.
